Cala kIQ Plus: The First Wearable Neurostimulator With Multiple Waveform Modes Goes National
BiohackingWearable neuromodulation has existed in clinical circles for years, but the devices remained locked in single-protocol approaches — one waveform for everyone, regardless of individual response. The Cala kIQ Plus is the first wearable to break from that model with adaptive, multi-mode stimulation for hand tremor.
What Happened
San Mateo-based Cala has launched nationwide availability of the kIQ Plus System, its next-generation wearable neuromodulation device for action hand tremor associated with essential tremor and Parkinson’s disease. The device received FDA clearance earlier in 2026 and is now available to patients across the United States, including through Veterans Affairs at no cost to eligible beneficiaries and with Medicare coverage for qualifying patients.
The device is the first of its kind to combine multiple stimulation waveform modes with adaptive calibration, allowing patients to personalize treatment based on individual response patterns rather than a single fixed protocol.
Why It Matters
Action hand tremor — the involuntary shaking that occurs during intentional movement — significantly impairs quality of life for people with essential tremor and Parkinson’s disease. It affects fine motor tasks: writing, eating, handling small objects. Non-invasive wearable treatments have been an active area of research precisely because the alternative (deep brain stimulation) requires surgery with corresponding risk.
The clinical evidence for the kIQ Plus centers on a study presented at the American Academy of Neurology meeting. Participants selecting their preferred waveform from the three available modes achieved notably greater improvements on the TETRAS (Tremor Research Group Essential Tremor Rating Scale) performance score — the standard clinician-rated tremor assessment. Between 76% and 89% of participants showed at least a one-point reduction on that scale with their preferred waveform.
The 76–89% range reflects a meaningful clinical signal for this patient population: a one-point reduction on the TETRAS scale corresponds to a detectable functional improvement in tremor-impaired tasks. The adaptive calibration feature matters because individual neurological response to stimulation is highly variable — the ability to select a waveform based on personal response addresses what single-protocol devices could not.
For the broader wearable health monitoring space, the kIQ Plus represents a meaningful architectural shift. Advanced clinical wearables like the Medtronic-Corsano platform have been moving toward continuous monitoring with closed-loop feedback. The kIQ Plus extends that approach into active neuromodulation therapy — not just observing physiology but adjusting it through personalized stimulation parameters.
The So What
Essential tremor affects an estimated 7 million Americans; Parkinson’s affects roughly 1 million more. The path to wearable neurostimulation for this population has historically run through clinical trial enrollment or surgical procedures. Nationwide availability of an FDA-cleared device with Medicare coverage and VA access changes that access profile meaningfully. For anyone in the affected population or advising someone who is, the kIQ Plus is the current clinical benchmark for non-invasive wearable treatment of action hand tremor, and it is now a routine referral option rather than an experimental one.
Source: Longevity Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →